Although TMB and MSI are typically predictive of favorable immunotherapy outcomes due to increased neoantigen load and immune activation [20,21], our findings suggest that DDR1 may counteract these benefits by fostering an immune-excluded tumor microenvironment. This evidence concerns the gene DDR1 and neoplasm.